XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability. Speaking at the 2026 TD Cowen Neuropsychiat

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal seizures, which originate in a specific area of the brain. The same announcement disclosed a voluntary pause in new enrollment […]

Wall Street reacts as the drugmaker’s experimental medication hits a roadblock.

Companies in The News Are: STLD,XENE,AMD,TXN

Key Stats for Xenon Pharmaceuticals StockPrice change for Xenon Pharmaceuticals stock: -31%$XENE Stock Price as of Sep. 19: $4052-Week High: $73$XENE Stock Price Target: $78What Happened?Xenon Pharmaceuticals (XENE) stock is under pressure after the company paused enrollment in its Phase 3 psychiatry studies for major depressive disorder and bipolar disorder.

Earlier this month, Xenon Pharmaceuticals submitted a New Drug Application to the US FDA for azetukalner in focal seizures, supported by two randomized, double-blind, placebo-controlled trials showing statistically significant seizure reduction and a generally consistent safety profile across more than 1,500 patient-years of exposure. On the same day, the company voluntarily paused new enrollment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric...

Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a 10-month low.

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree

Xenon Pharmaceuticals stock sinks as the company halts enrollment of new patients in a key trial. Here’s how you should play XENE shares at current levels.

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent with azetukalner's known safety profile, Xenon said, but had not...

Xenon Pharmaceuticals' (XENE) enrollment pause in an ongoing phase 3 trial of azetukalner adds risk

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical company announced a voluntary pause on new patient enrollment in its ongoing depression clinical studies following reports of neuropsychiatric adverse events. Positive Data Drives FDA Submission The regulatory filing relies on clinical data from the Phase 2b X

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.

Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.

On August 26, Xenon Pharmaceuticals (NASDAQ:XENE) announced that it will deliver six data presentations at the 16th European Epilepsy Congress in Athens, Greece, running September 5 through 9. The headline slot is an oral presentation of topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures, alongside two posters covering patients […]

Xenon Pharmaceuticals recently announced that it presented multiple new data sets on its lead asset azetukalner at the 16th European Epilepsy Congress in Athens, including topline Phase 3 X‑TOLE2 results in focal onset seizures and long‑term open‑label extension findings. Beyond efficacy and safety updates, Xenon highlighted mechanistic data suggesting azetukalner may offer additive benefits in combination with commonly used anti‑seizure medications, underscoring its potential role in...

Azetukalner advances toward FDA submission as pain pipeline matures.

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter. Chief Executive Offi

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared construct

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Xenon Pharmaceuticals Inc (XENE) reports robust pipeline progress and $1.2 billion in cash, funding operations into 2029 as it prepares for regulatory submission.

With EPS growth for the next five years forecasted at 31.63%, Biohaven Ltd. (NYSE:BHVN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 29, BofA downgraded Biohaven Ltd. (NYSE:BHVN) to Underperform from Neutral and lowered its price target to $11 from $12, citing a more cautious view of the […]